0001209191-21-007560.txt : 20210203 0001209191-21-007560.hdr.sgml : 20210203 20210203200840 ACCESSION NUMBER: 0001209191-21-007560 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210201 FILED AS OF DATE: 20210203 DATE AS OF CHANGE: 20210203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McAnear Justin J. CENTRAL INDEX KEY: 0001786386 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39035 FILM NUMBER: 21588282 MAIL ADDRESS: STREET 1: 10X GENOMICS, INC. STREET 2: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 10x Genomics, Inc. CENTRAL INDEX KEY: 0001770787 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 455614458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: (925) 401-7300 MAIL ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: 10X Genomics, Inc. DATE OF NAME CHANGE: 20190315 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-01 0 0001770787 10x Genomics, Inc. TXG 0001786386 McAnear Justin J. C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 0 1 0 0 Chief Financial Officer Class A Common Stock 2021-02-01 4 M 0 10000 5.04 A 30774 D Class A Common Stock 2021-02-01 4 S 0 600 174.1817 D 30174 D Class A Common Stock 2021-02-01 4 S 0 5213 175.5279 D 24961 D Class A Common Stock 2021-02-01 4 S 0 2777 176.5109 D 22184 D Class A Common Stock 2021-02-01 4 S 0 910 177.5002 D 21274 D Class A Common Stock 2021-02-01 4 S 0 500 178.494 D 20774 D Stock Option (right to buy) 5.04 2021-02-01 4 M 0 10000 0.00 D 2028-11-02 Class A Common Stock 10000 460159 D The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $173.50 to $174.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $175.00 to $175.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $176.02 to $177.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $177.03 to $177.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $178.11 to $178.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This option, originally for 600,000 shares, of which 139,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. /s/ Eric S. Whitaker, as Attorney-in-Fact 2021-02-03